342 related articles for article (PubMed ID: 19425902)
1. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.
Borah BJ; Huang X; Zarotsky V; Globe D
Curr Med Res Opin; 2009 Jun; 25(6):1365-77. PubMed ID: 19425902
[TBL] [Abstract][Full Text] [Related]
2. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
4. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
[TBL] [Abstract][Full Text] [Related]
5. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.
Wu E; Chen L; Birnbaum H; Yang E; Cifaldi M
Curr Med Res Opin; 2007 Aug; 23(8):1749-59. PubMed ID: 17588306
[TBL] [Abstract][Full Text] [Related]
6. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
[TBL] [Abstract][Full Text] [Related]
7. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept.
Yazdani C; McLaughlin T; Cummins G; Doyle J
Am J Manag Care; 2001 Sep; 7(13 Suppl):S419-26. PubMed ID: 11594238
[TBL] [Abstract][Full Text] [Related]
8. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans.
Joyce AT; Gandra SR; Fox KM; Smith TW; Pill MW
J Med Econ; 2014 Jan; 17(1):1-10. PubMed ID: 24131136
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.
Bonafede MM; Gandra SR; Fox KM; Wilson KL
J Med Econ; 2012; 15(4):635-43. PubMed ID: 22332705
[TBL] [Abstract][Full Text] [Related]
10. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
11. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population.
Ollendorf DA; Peterson AN; Doyle J; Huse DM
Am J Manag Care; 2002 May; 8(7 Suppl):S203-13. PubMed ID: 12022236
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
13. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
Tang B; Rahman M; Waters HC; Callegari P
Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
[TBL] [Abstract][Full Text] [Related]
14. Utilization and adherence patterns of subcutaneously administered anti-tumor necrosis factor treatment among rheumatoid arthritis patients.
Tkacz J; Ellis L; Bolge SC; Meyer R; Brady BL; Ruetsch C
Clin Ther; 2014 May; 36(5):737-47. PubMed ID: 24661783
[TBL] [Abstract][Full Text] [Related]
15. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice.
Huang X; Gu NY; Fox KM; Harrison DJ; Globe D
Curr Med Res Opin; 2010 Jul; 26(7):1637-45. PubMed ID: 20429830
[TBL] [Abstract][Full Text] [Related]
16. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
17. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.
Du Pan SM; Dehler S; Ciurea A; Ziswiler HR; Gabay C; Finckh A;
Arthritis Rheum; 2009 May; 61(5):560-8. PubMed ID: 19405000
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Costs in Biologic DMARD-Naive Patients with Rheumatoid Arthritis Initiating Etanercept or Adalimumab with or Without Methotrexate.
Tkacz J; Gharaibeh M; DeYoung KH; Wilson K; Collier D; Oko-Osi H
J Manag Care Spec Pharm; 2020 Mar; 26(3):285-294. PubMed ID: 32105179
[TBL] [Abstract][Full Text] [Related]
19. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
Harley CR; Frytak JR; Tandon N
Am J Manag Care; 2003 Oct; 9(6 Suppl):S136-43. PubMed ID: 14577718
[TBL] [Abstract][Full Text] [Related]
20. Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.
McBride S; Sarsour K; White LA; Nelson DR; Chawla AJ; Johnston JA
J Rheumatol; 2011 Oct; 38(10):2141-9. PubMed ID: 21844154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
